Catalog Products » Antibodies » Primary Antibodies » Cytokine and Growth Factor Antibodies » Vascular Endothelial Growth Inhibitor (VEGI), Human
Email to GenScript
Search by Catalog Number :
Search by Name :
Search by Sequence : (One letter code)
Search by Category :

Vascular Endothelial Growth Inhibitor (VEGI), Human

Cat. No.
Product Name
Z02198-50 VEGI, Human
50 μg

Protein Vascular Endothelial Growth Inhibitor (VEGI), Human
VEGI (Human); VEGI-192; rHuVEGI;
VEGI, HumanDocument-MSDS: 15138_20111230005124.PDF (PDF)
VEGI, HumanDocument-MSDS: Z02198_MSDS.pdf (pdf)
The purity of GenScript Recombinant Human VEGI-192 is greater than 95.0%, as determined by the following methods:
(a) RP-HPLC analysis
(b) Reducing and non-reducing SDS-PAGE silver-stained gel analysis
Endotoxin Level
The endotoxin level of GenScript Recombinant Human VEGI-192 is below 0.1 ng/µg (1 IEU/µg) of rHuVEGI.
The ED50, as determined by the dose-dependant inhibition of the proliferation of HUVEC (Human Umbilical Vein Endothelial Cells), is less than 5 μg/ml.
E. coli
Amino Acid Sequence
The sequence of the
first five N-terminal amino
acids has been found
to be Met-Gln-Leu-Thr-Lys.
Molecular Weight
21,858 Da
Vascular endothelial growth inhibitor (VEGI; TNFSF-15) is a new member of the tumor necrosis factor family. VEGI is predominantly an endothelial cell-specific gene, and recombinant VEGI is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. VEGI exerts two activities on endothelial cells: early G1 arrest of G0/G1-cells responding to growth stimuli, and programmed death of proliferating cells. These activities are highly specific to endothelial cells. VEGI is also able to regulate the expression of several important genes involved in angiogenesis. These findings are consistent with the view that VEGI functions as an autocrine cytokine to inhibit angiogenesis and stabilize the vasculature.
GenScript Vascular Endothelial Growth Inhibitor (VEGI), human, produced in E. coli, is a single, non-glycosylated polypeptide chain containing 192 amino acids and having a molecular mass of 21,858 Da.
GenScript Recombinant Human VEGI-192 is lyophilized after extensive dialysis against 0.5 M NaCl, 50 mM Tris-HCl buffer, pH 7.5.
It is recommended that the lyophilized VEGI-192 be reconstituted in sterile 18 MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.
Although lyophilized VEGI-192 can remain stable at room temperature for up to three weeks, it is best stored desiccated below -18°C. After reconstitution, VEGI-192 may be stored at 4°C for up to seven days and below -18°C for longer periods. For long-term storage, it is recommended that a carrier protein (0.1% HSA or BSA) be added. Please avoid freeze-thaw cycles.
  • C51161408_Z02198_COA
  • C51161408_Z02198_COA.pdf
  • 1
    Custom Recombinant Protein Services: Guaranteed E. coli Expression Package-3 mg purified soluble protein from $2,200 .
    Bacterial Expression System: GenScript has developed BacPowerTM technologies to tackle hard-to-express and hard-to-dissolve proteins.
    Yeast Expression System: GenScript's proprietary YeastHIGHTM technology combines the advantages of the bacterial and eukaryotic expression systems.
    Baculovirus/Insect Cell Expression System: GenScript developed BacuVanceTM platform for the secretion of recombinant proteins from baculovirus-infected insect cells.
    Mammalian Cell Expression System: The proprietary 293 and CHO suspension system platform promotes fast production and delivery of recombinant proteins and monoclonal antibodies up to grams level.